Consumer Products
Personal Care
Biopharmaceutical

Veru

$1.54
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.02 (-1.28%) Today
-$0.02 (-1.28%) Today

Why Robinhood?

You can buy or sell Veru and other stocks, options, ETFs, and crypto commission-free!

About

Veru Inc. Common Stock, also called Veru, is a urology and oncology biopharmaceutical company, which engages in the development, manufacture and marketing of consumer health care products. Read More It operates through the Commercial; and Research and Development segments. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. The company was founded by William R. Gargiulo Jr. and O.B. Parrish in 1971 and is headquartered in Miami, FL.

Employees
171
Headquarters
Miami, Florida
Founded
1971
Market Cap
97.68M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
121.51K
High Today
$1.62
Low Today
$1.48
Open Price
$1.62
Volume
142.36K
52 Week High
$2.37
52 Week Low
$1.18

Collections

Consumer Products
Personal Care
Biopharmaceutical
Advertising and Marketing
Healthcare
Research And Development
Retail
Pharmaceutical

News

MarketWatchMar 19

Veru Inc. Stock Quote (U.S.: Nasdaq)

Veru (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. on Zacks.com...

66
MarketBeatMar 5

NASDAQ:VERU - Stock Price, News, & Analysis for Veru

Veru Inc. operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequi...

45

Earnings

-$0.15
-$0.11
-$0.07
-$0.03
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected May 8, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.